Montana Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• New Risk Score Helps Identify Bleeding Risk With DOACs in Cancer-Associated VTE
  The novel ONCO-DOAC BLEED risk score, developed by Tomoyuki Nagai, MD, et al., provided clinically relevant major bleeding risk stratification for patients with cancer-associated venous thromboembolism (VTE) receiving direct oral anticoagulants (DOAC), according to research published June 16 in JACC: CardioOncology.
• MAPLE-HCM Analysis: Aficamten Monotherapy Superior to Metoprolol in Combating Exercise Intolerance in oHCM
  Aficamten monotherapy was superior to metoprolol in promoting adaptation to multiple phases of exercise in patients with symptomatic obstructive HCM (oHCM), according to a prespecified analysis of the MAPLE-HCM trial published June 17 in JAMA Cardiology.
• Clopidogrel May Offer Long-Term Edge Over Aspirin After PCI
  Clopidogrel monotherapy was associated with lower risks of major adverse cardiovascular events (MACE) and major bleeding compared with aspirin monotherapy among stable patients post PCI, according to a nationwide cohort study published June 15 in JACC: Asia.
• Long-Term Exposure to PM2.5 Components Increases CVD Risk
  Long-term exposure to specific chemical components of fine particulate matter with diameters ≤2.5 μm (PM2.5) was associated with an increased risk of developing cardiovascular disease, according to a large cohort study published June 24 in JACC.
• PARTNER 2A, P2S3i Registry: 10-Year TAVR Outcomes With SAPIEN XT, SAPIEN 3
  The rates of mortality and reintervention at 10 years were higher in patients at intermediate risk who underwent TAVR with the second-generation SAPIEN XT valve than those who underwent surgery in the PARTNER 2A trial, according to an analysis published June 16 in a valvular heart disease focus issue of JACC.